Company: ABBV
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001551152-25-000049
Chunk: 50

Company: AbbVie Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
$1.64 06/21/2408/15/24$1.55 02/13/2505/15/25$1.64 02/15/2405/15/24$1.55 Stock Repurchase ProgramThe company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. AbbVie repurchased 3 million shares for $606 million during the nine months ended September 30, 2025 and 5 million shares for $959 million during the nine months ended September 30, 2024. AbbVie's remaining stock repurchase authorization was approximately $2.9 billion as of September 30, 2025.Accumulated Other Comprehensive Loss The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2025:(in millions)Foreign currency translation adjustmentsNet investmenthedging activitiesPension and post-employment benefitsCash flow hedging activitiesTotalBalance as of December 31, 2024$(2,114)$549 $(664)$304 $(1,925)Other comprehensive income (loss) before reclassifications1,489 (885)3 (105)502 Net losses (gains) reclassified from accumulated other comprehensive loss— (85)2 (68)(151)Net current-period other comprehensive income (loss)1,489 (970)5 (173)351 Balance as of September 30, 2025$(625)$(421)$(659)$131 $(1,574)Other comprehensive income for the nine months ended September 30, 2025 included foreign currency translation adjustments totaling a gain of $1.5 billion principally due to the impact of the strengthening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling a loss of $970 million.

2025 Form 10-Q | 20

The following table summarizes the changes in each component of accumulated other